Organoid-driven nanomedicine platform development

Jian Wang¹, Fuxiao Wang², Yingying Jiang², Long Bai³, Xiaoyuan Chen⁴, Jiacan Su⁵

Affiliations

¹ MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China; Department of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
² MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China.
³ MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China. Electronic address: bailong@shu.edu.cn.
⁴ Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074; Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575; Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore, 117544; Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599; Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597; Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 138667; Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A∗STAR), Singapore, 138673. Electronic address: chen.shawn@nus.edu.sg.
⁵ MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China; Department of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. Electronic address: jiacansu@shu.edu.cn.

PMID: 40795706
DOI: 10.1016/j.biomaterials.2025.123611

Review

Organoid-driven nanomedicine platform development

Jian Wang et al. Biomaterials. 2026 Feb.

. 2026 Feb:325:123611.

doi: 10.1016/j.biomaterials.2025.123611. Epub 2025 Aug 7.

Authors

Jian Wang¹, Fuxiao Wang², Yingying Jiang², Long Bai³, Xiaoyuan Chen⁴, Jiacan Su⁵

Affiliations

¹ MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China; Department of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
² MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China.
³ MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China. Electronic address: bailong@shu.edu.cn.
⁴ Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074; Department of Chemical and Biomolecular Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575; Department of Biomedical Engineering, College of Design and Engineering, National University of Singapore, Singapore, 117575; Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore, 117544; Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599; Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597; Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 138667; Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A∗STAR), Singapore, 138673. Electronic address: chen.shawn@nus.edu.sg.
⁵ MedEng-X Institutes, Shanghai University, Shanghai, 200444, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China; National Center for Translational Medicine SHU Branch, Shanghai University, Shanghai, 200444, China; Department of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. Electronic address: jiacansu@shu.edu.cn.

PMID: 40795706
DOI: 10.1016/j.biomaterials.2025.123611

Abstract

The integration of organoid models with nanomedicine delivery systems offers a novel approach to drug discovery and personalized medicine by enabling more accurate, efficient, and physiologically relevant evaluation of therapeutic efficacy. Organoids, three-dimensional (3D) cell structures cultivated in vitro from stem cells or adult stem cells, mimic the architecture and functionality of human tissues, providing a more accurate platform for disease modeling, drug screening, and toxicity testing compared to traditional two-dimensional (2D) cell cultures. Meanwhile, nanomedicine delivery systems have garnered significant attention in pharmaceutical research due to their ability to enhance drug stability, control drug release, and target specific tissues. The combination of organoid technology and nanomedicine platforms holds immense potential to advance drug development and improve individualized therapeutic strategies. This review aims to summarize recent advancements in organoid-driven nanomedicine platforms, explore their applications in drug screening, toxicological evaluation, and personalized medicine, and address the challenges and future directions in this emerging field.

Keywords: Drug screening; Nanomedicine; Organoid; Personalized medicine; Targeted delivery; Toxicological evaluation.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Organoid-driven nanomedicine platform development

Affiliations

Organoid-driven nanomedicine platform development

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources